Biopharma Co. Adds CTO to Team September 22, 2023 (Investorideas.com Newswire) This newest member brings with him extensive experience in protein development and manufacturing

Trial Results Validate New Drug-Delivering Nasal Implant September 21, 2023 (Investorideas.com Newswire) This product candidate presents a compelling approach to treating post-surgery chronic rhinosinusitis patients

Biotech Co. Makes Strides on Three Fronts September 20, 2023 (Investorideas.com Newswire) This Canadian firm sold assets, launched an equity raise and filed a clinical trial application for its lead psychedelic-assisted psychotherapy program

Telehealth Co. Signs Contract With Client in Eight States September 14, 2023 (Investorideas.com Newswire) This telehealth company has signed a new contract for its remote patient monitoring platform to be used by a leading healthcare company with dozens of locations in eight states.

Telehealth Co. Expands Platform To Cover Pediatric Patients September 11, 2023 (Investorideas.com Newswire) This telehealth company is expanding its platform to cover remote monitoring for pediatric patients with diabetes and other eligible conditions.

Co. Reaches Major Milestone With Novel Drug September 8, 2023 (Investorideas.com Newswire) The biopharma initiated enrollment of a targeted 420 patients for one of its Phase 3 clinical trials evaluating its new cardiac myosin inhibitor

Cryoablation System Gets Approved in Brazil September 8, 2023 (Investorideas.com Newswire) The product developer expects to generate US$6.6 million in sales of this medical device in Brazil over the next five years

FTC Settles Suit, Potentially Averting Further Hurdles September 7, 2023 (Investorideas.com Newswire) McAlinden Research shares a deep dive into a market driver with alpha-generating potential.

After Seeing 86% Success Rate in Phase 2, Biotech Co. Moves to Phase 3 for AUD Treatment September 7, 2023 (Investorideas.com Newswire) Awakn Life Sciences has applied for Phase 3 of clinical trials after the success of Phase 2.

Contract Adding Thousands of Patients to Co.'s Telehealth Platform September 6, 2023 (Investorideas.com Newswire) This telehealth company has signed a new contract with a Texas respiratory clinic that is expected to add 10,000 new patients to its iUGO platform by mid-2024.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

The Rise of Mobile Applications in Healthcare and Medicine - September 5, 2023

How to Prove Wrongful Death - February 1, 2022

Healthcare Supply Chain Management Software - November 29, 2021

Overview of Biotech Stocks - What Could Happen by the End of 2021? - November 3, 2021

Consider Investing In These Disruptive Medical Companies In 2021 - April 16, 2021

Resources for Physicians and Medical Practices - December 31, 2020

Lockdown Part 2: The South African Economy and the Rand - December 15, 2020

How to Get Into Canada during COVID - November 30, 2020

The Impact of Gynecomastia on Your Mental Health and How to Deal With the Condition - September 8, 2020

Does Income Protection Cover Me for a COVID Redundancy? - August 10, 2020

Everything You Need to Know About Investing in Healthcare Stocks - March 30, 2020

The Rise Of The At-Home Testing Market - January 16, 2020

Why Do You Need Birth Injury Lawyer and How They Can Help You? - October 2, 2019

5 Key Tips For Renting a Boardroom - August 14, 2018

How to Go About Choosing a Medical Malpractice Lawyer - February 13, 2018

Mindset Pharma Announces Mailing of Circular and Receipt of Interim Order Toronto, Ontario--(Newsfile Corp. - September 22, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") announces that, further to its press release of August 31, 2023, its management information circular (the "Circular") and related materials were mailed today, September 22, 2023, for its special meeting (the "Meeting") of the Company's shareholders (the "Shareholders") to approve a statutory plan of arrangement (the "Arrangement") involving, among...

Defence to Collaborate with Native Ads for Marketing Campaign Vancouver, British Columbia--(Newsfile Corp. - September 22, 2023) - Defence Therapeutics Inc.  (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce it has entered into a service agreement with Native Ads Inc. ("Native Ads"), pursuant to which Native Ads will provide a marketing campaign for a total retainer of up to US$250,000,...

Skye Bioscience Announces Participation at Upcoming Investor Conferences San Diego, California--(Newsfile Corp. - September 22, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes, with a current focus on the CB1 pathway, announced today that it will be presenting a corporate overview at the 2023 Cantor Global Healthcare Conference and the 16th Annual LD Micro Main Event.2023...

Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 21, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 9, 2023 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors and in favor of resolutions amending the...

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years Encinitas, California--(Newsfile Corp. - September 21, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced that its board of directors has appointed Praveen Tyle, PhD, who currently serves as a director, as its new Chairman. Dr. Tyle succeeds current Chairman Paul Chaney who is retiring after serving 17 years on the board."We look forward to Dr. Tyle's leadership as Chairman, where he'll continue to bring valuable industry experience in guiding our development of new treatments for eye...

Subscribe to Biotech News